Literature DB >> 19112176

Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1.

Sang Hwa Kim1, Yuling Shi, Keith A Hanson, Leah M Williams, Ryo Sakasai, Michael J Bowler, Randal S Tibbetts.   

Abstract

TDP-43 (43-kDa TAR DNA-binding domain protein) is a major constituent of ubiquitin-positive cytoplasmic aggregates present in neurons of patients with fronto-temporal lobular dementia and amyotrophic lateral sclerosis (ALS). The pathologic significance of TDP-43 aggregation is not known; however, dominant mutations in TDP-43 cause a subset of ALS cases, suggesting that misfolding and/or altered trafficking of TDP-43 is relevant to the disease process. Here, we show that the presenilin-binding protein ubiquilin 1 (UBQLN) plays a role in TDP-43 aggregation. TDP-43 interacted with UBQLN both in yeast and in vitro, and the carboxyl-terminal ubiquitin-associated domain of UBQLN was both necessary and sufficient for binding to polyubiquitylated forms of TDP-43. Overexpression of UBQLN recruited TDP-43 to detergent-resistant cytoplasmic aggregates that colocalized with the autophagosomal marker, LC3. UBQLN-dependent aggregation required the UBQLN UBA domain, was mediated by non-overlapping regions of TDP-43, and was abrogated by a mutation in UBQLN previously linked to Alzheimer disease. Four ALS-associated alleles of TDP-43 also coaggregated with UBQLN, and the extent of aggregation correlated with in vitro UBQLN binding affinity. Our findings suggest that UBQLN is a polyubiquitin-TDP-43 cochaperone that mediates the autophagosomal delivery and/or proteasome targeting of TDP-43 aggregates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19112176      PMCID: PMC2658102          DOI: 10.1074/jbc.M808064200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons.

Authors:  T L Williamson; D W Cleveland
Journal:  Nat Neurosci       Date:  1999-01       Impact factor: 24.884

2.  The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease.

Authors:  Christine Vande Velde; Michael L Garcia; Xinghua Yin; Bruce D Trapp; Don W Cleveland
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

3.  Family-based association between Alzheimer's disease and variants in UBQLN1.

Authors:  Lars Bertram; Mikko Hiltunen; Michele Parkinson; Martin Ingelsson; Christoph Lange; Karunya Ramasamy; Kristina Mullin; Rashmi Menon; Andrew J Sampson; Monica Y Hsiao; Kathryn J Elliott; Gonül Velicelebi; Thomas Moscarillo; Bradley T Hyman; Steven L Wagner; K David Becker; Deborah Blacker; Rudolph E Tanzi
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

4.  Axonal transport of mutant superoxide dismutase 1 and focal axonal abnormalities in the proximal axons of transgenic mice.

Authors:  D R Borchelt; P C Wong; M W Becher; C A Pardo; M K Lee; Z S Xu; G Thinakaran; N A Jenkins; N G Copeland; S S Sisodia; D W Cleveland; D L Price; P N Hoffman
Journal:  Neurobiol Dis       Date:  1998-07       Impact factor: 5.996

5.  Acidification is essential for maintaining the structure and function of lytic granules of CTL. Effect of concanamycin A, an inhibitor of vacuolar type H(+)-ATPase, on CTL-mediated cytotoxicity.

Authors:  T Kataoka; K Takaku; J Magae; N Shinohara; H Takayama; S Kondo; K Nagai
Journal:  J Immunol       Date:  1994-11-01       Impact factor: 5.422

6.  Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases.

Authors:  S Dröse; K U Bindseil; E J Bowman; A Siebers; A Zeeck; K Altendorf
Journal:  Biochemistry       Date:  1993-04-20       Impact factor: 3.162

7.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

8.  Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance.

Authors:  Emanuele Buratti; Antonia Brindisi; Franco Pagani; Francisco E Baralle
Journal:  Am J Hum Genet       Date:  2004-06       Impact factor: 11.025

9.  Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis.

Authors:  Nicola J Rutherford; Yong-Jie Zhang; Matt Baker; Jennifer M Gass; Nicole A Finch; Ya-Fei Xu; Heather Stewart; Brendan J Kelley; Karen Kuntz; Richard J P Crook; Jemeen Sreedharan; Caroline Vance; Eric Sorenson; Carol Lippa; Eileen H Bigio; Daniel H Geschwind; David S Knopman; Hiroshi Mitsumoto; Ronald C Petersen; Neil R Cashman; Mike Hutton; Christopher E Shaw; Kevin B Boylan; Bradley Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Richard J Caselli; Dennis W Dickson; Ian R Mackenzie; Leonard Petrucelli; Rosa Rademakers
Journal:  PLoS Genet       Date:  2008-09-19       Impact factor: 5.917

Review 10.  Autophagy in neurodegeneration and development.

Authors:  Ashley R Winslow; David C Rubinsztein
Journal:  Biochim Biophys Acta       Date:  2008-07-01
View more
  62 in total

Review 1.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

2.  Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation.

Authors:  Annakaisa Haapasalo; Jayashree Viswanathan; Kaisa Ma Kurkinen; Lars Bertram; Hilkka Soininen; Nico P Dantuma; Rudolph E Tanzi; Mikko Hiltunen
Journal:  Commun Integr Biol       Date:  2011-07-01

3.  Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA.

Authors:  Sang Hwa Kim; Naval P Shanware; Michael J Bowler; Randal S Tibbetts
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 4.  Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease.

Authors:  Seth A Bennett; Royena Tanaz; Samantha N Cobos; Mariana P Torrente
Journal:  Transl Res       Date:  2018-10-12       Impact factor: 7.012

5.  Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability.

Authors:  Antonella Caccamo; Smita Majumder; Janice J Deng; Yidong Bai; Fiona B Thornton; Salvatore Oddo
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

6.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.

Authors:  Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-03-18       Impact factor: 17.088

7.  Ubiquilin-1 protects cells from oxidative stress and ischemic stroke caused tissue injury in mice.

Authors:  Yanying Liu; Lanhai Lü; Casey L Hettinger; Gaofeng Dong; Dong Zhang; Khosrow Rezvani; Xuejun Wang; Hongmin Wang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

8.  Ushering in the cardiac role of Ubiquilin1.

Authors:  Xi Fang; Christa Trexler; Ju Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

Review 9.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

10.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease.

Authors:  Jeong-Sun Ju; Rodrigo A Fuentealba; Sara E Miller; Erin Jackson; David Piwnica-Worms; Robert H Baloh; Conrad C Weihl
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.